Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Non-Hodgkin's lymphoma initial studies may use historical controls -- FDA advisory committee.

Executive Summary

NON-HODGKIN's LYMPHOMA AGENT INITIAL STUDIES: HISTORICAL CONTROLS ACCEPTABLE to determine whether response rates reflect meaningful clinical benefit over existing therapies, members of FDA's Biological Response Modifiers Advisory Committee agreed at an Oct. 21 meeting. The committee discussed clinical trial issues for drugs and biologics being developed for non-Hodgkin's lymphoma in the context of FDA's oncologics initiative.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts